Clinical Trials | March 11, 2026
Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The company announced positive topline data from the Phase II ZUPREME-1 trial
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Subscribe To Our Newsletter & Stay Updated
